Olexa Peter, Habiňáková Martina, Koval Štefan
Vnitr Lek. 2020 Winter;66(8):5-11.
Atrial fibrillation (AF) is a problem of growing prevalence as a consequence of the ageing population, is associated with high morbidity, mortality, and healthcare costs. The risk is significantly reduced by oral anticoagulation. Adherence to guidelines may lower the risks for both all cause and cardiovascular (CV) deaths.
Our objective was to evaluate the type and adherence of prescribed antithrombotic treatment according to the 2012 and 2016 European Society of Cardiology (ESC) guidelines in studied group of consecutive patients managed in private cardiology office in years 2012 and 2017. Only patients with diagnosis of AF were analysed. We aimed to prove, if nonadherence is associated with higher rate of adverse outcomes. Data were obtained from consecutive patients managed in private cardiology office in years 2012 and 2017. Only patients with diagnosis of AF older than 65 years were analysed.
Among 2 850 patients examined in 2012, 213 (8 %) were discharged with a diagnosis of AF. In 2017 we examined 4 389 patients, 401 (9 %) diagnosed with AF, among them 350 older than 65 (87.5%). Median age in both groups was 76 ys. Significant differences in the frequency and type of anticoagulation therapy were observed between 2012 and 2016 - warfarin was used in 102 (47 %) vs 110 (31 %), NOACs in 25 (12 %) vs 189 (54 %), ASA or clopidogrel in 68 (32 %) vs. 41 (12 %). None antitrombotics were used in 20 (10 %) vs 10 (3 %). Based on ESC guidelines, both groups were divided into two subgroups according to the guideline adherence to proper anticoagulation therapy. The quality of medical treatment increased significantly from 2012 to 2017. 61 % of patients were on guideline-adherent thromboprophylaxis, 39 % were undertreated in 2012, while in 2017 the guidelines were followed much better - 14 % were undertreated vs 86 % treated properly. We examined statistically the importance of age, frailty, history of ischaemic stroke, minor heamorhage, and values of CHADS2 and HASBLED indexes for the nonadherence to Guideline aproved antitrombotic management. Series of binary logistic analyses showed that increasing age (p = 0.05), and concomitant history of minor bleeding (p = 0.003) were associated with undertreatment in 2012, while in 2017 HASBLED score (p < 0.051), nor other studied factor led to non-adherence to Guideline aproved therapy. AF patients who were guideline adherent had a lower rate of all-cause death (p = 0.007) compared to those non-adherent. Binary logistic regresion analysis showed that guideline-nonadherent patients had a higher risk for all-cause mortality (p = 0.003).
Non-adherence to guidelines is currently less prevalent among elderly AF patients compared to clinical treatment in previous years. Proper Guideline-adherent treatment is being independently associated with lower risk of all-cause mortality. Efforts to improve guideline adherence would lead to better outcomes for elderly and frail AF patients.
由于人口老龄化,心房颤动(AF)的患病率日益增加,它与高发病率、死亡率及医疗费用相关。口服抗凝治疗可显著降低风险。遵循指南可能会降低全因死亡和心血管(CV)死亡的风险。
我们的目的是根据2012年和2016年欧洲心脏病学会(ESC)指南,评估2012年和2017年在私立心脏病诊所接受治疗的连续患者组中规定的抗栓治疗的类型和依从性。仅分析诊断为AF的患者。我们旨在证明不依从是否与更高的不良结局发生率相关。数据来自2012年和2017年在私立心脏病诊所接受治疗的连续患者。仅分析年龄大于65岁的诊断为AF的患者。
2012年检查的2850例患者中,213例(8%)出院诊断为AF。2017年我们检查了4389例患者,401例(9%)诊断为AF,其中350例年龄大于65岁(87.5%)。两组的中位年龄均为76岁。2012年和2016年之间观察到抗凝治疗的频率和类型存在显著差异——华法林的使用比例为102例(47%)对110例(31%),新型口服抗凝药(NOACs)为25例(12%)对189例(54%),阿司匹林或氯吡格雷为68例(32%)对41例(12%)。未使用任何抗栓药物的比例为20例(10%)对10例(3%)。根据ESC指南,两组根据对适当抗凝治疗的指南依从性分为两个亚组。从2012年到2017年,医疗质量显著提高。2012年61%的患者接受了符合指南的血栓预防,39%的患者治疗不足,而在2017年,遵循指南的情况要好得多——14%的患者治疗不足,86%的患者得到了适当治疗。我们从统计学上检验了年龄、虚弱、缺血性中风病史、轻微出血以及CHADS2和HASBLED指数值对不遵循指南批准的抗栓治疗管理的重要性。一系列二元逻辑回归分析表明,年龄增加(p = 0.05)和伴有轻微出血病史(p = 0.003)与2012年治疗不足相关,而在2017年,HASBLED评分(p < 0.051)以及其他研究因素均未导致不遵循指南批准的治疗。与不遵循指南的AF患者相比,遵循指南的AF患者全因死亡率较低(p = 0.007)。二元逻辑回归分析表明,不遵循指南的患者全因死亡风险较高(p = 0.003)。
与前几年的临床治疗相比,目前老年AF患者中不遵循指南的情况不太普遍。适当遵循指南的治疗与较低的全因死亡风险独立相关。努力提高指南依从性将为老年和体弱的AF患者带来更好的结局。